AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Paris, France; Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France.
CHU Lille, Clinique de Pneumologie, Lille, France; Univ Lille, INSERM, LIRIC UMR U995, Lille, France.
Chest. 2021 Apr;159(4):1621-1629. doi: 10.1016/j.chest.2020.10.092. Epub 2020 Dec 5.
The decision-making on antiplatelet drug withdrawal or continuation before performing a pleural procedure is based on the balance between the risk of bleeding associated with the antiplatelet therapy and the risk of arterial thrombosis due to its interruption. Knowledge on antiplatelet therapy-associated risk of bleeding after pleural procedures is lacking.
Is the risk of bleeding associated with antiplatelet drugs increased in patients undergoing pleural procedures?
We conducted a French multicenter cohort study in 19 centers. The main outcome was the occurrence of bleeding, defined as hematoma, hemoptysis, or hemothorax, during the 24 h following a pleural procedure. Serious bleeding events were defined as bleeding requiring blood transfusion, respiratory support, endotracheal intubation, embolization, or surgery, or as death.
A total of 1,124 patients was included (men, 66%; median age, 62.6 ± 27.7 years), of whom 182 were receiving antiplatelet therapy and 942 were not. Fifteen patients experienced a bleeding event, including eight serious bleeding events. The 24-h incidence of bleeding was 3.23% (95% CI, 1.08%-5.91%) in the antiplatelet group and 0.96% (95% CI, 0.43%-1.60%) in the control group. The occurrence of bleeding events was significantly associated with antiplatelet therapy in univariate analysis (OR, 3.44; 95% CI, 1.14-9.66; P = .021) and multivariate analysis (OR, 4.13; 95% CI, 1.01-17.03; P = .044) after adjusting for demographic data and the main risk factors for bleeding. Likewise, antiplatelet therapy was significantly associated with serious bleeding in univariate analysis (OR, 8.61; 95% CI, 2.09-42.3; P = .003) and multivariate analysis (OR, 7.27; 95% CI, 1.18-56.1; P = .032) after adjusting for the number of risk factors for bleeding.
Antiplatelet therapy was associated with an increased risk of post-pleural procedure bleeding and serious bleeding. Future guidelines should take into account these results for patient safety.
在进行胸腔操作之前,关于抗血小板药物停药或继续使用的决策是基于抗血小板治疗相关出血风险与因中断治疗而导致的动脉血栓形成风险之间的平衡。缺乏关于抗血小板治疗后胸腔操作相关出血风险的知识。
接受胸腔操作的患者使用抗血小板药物是否会增加出血风险?
我们在 19 个中心进行了一项法国多中心队列研究。主要结局是在胸腔操作后 24 小时内发生出血,定义为血肿、咯血或血胸。严重出血事件定义为需要输血、呼吸支持、气管插管、栓塞或手术治疗或死亡的出血。
共纳入 1124 例患者(男性占 66%;中位年龄 62.6±27.7 岁),其中 182 例正在接受抗血小板治疗,942 例未接受抗血小板治疗。15 例患者发生出血事件,其中 8 例为严重出血事件。抗血小板治疗组 24 小时出血发生率为 3.23%(95%CI,1.08%-5.91%),对照组为 0.96%(95%CI,0.43%-1.60%)。单因素分析显示,出血事件的发生与抗血小板治疗显著相关(OR,3.44;95%CI,1.14-9.66;P=0.021),多因素分析也显示,在校正人口统计学数据和出血的主要危险因素后,抗血小板治疗与出血显著相关(OR,4.13;95%CI,1.01-17.03;P=0.044)。同样,抗血小板治疗与严重出血在单因素分析(OR,8.61;95%CI,2.09-42.3;P=0.003)和多因素分析(OR,7.27;95%CI,1.18-56.1;P=0.032)中也显著相关,校正出血风险因素的数量后。
抗血小板治疗与胸腔操作后出血和严重出血风险增加相关。未来的指南应考虑这些结果以确保患者安全。